E Gerdts

Summary

Country: Norway

Publications

  1. ncbi Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
    Eva Gerdts
    Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
    Hypertension 39:739-43. 2002
  2. ncbi Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study)
    E Gerdts
    Institute of Medicine, University of Bergen, Norway
    J Hum Hypertens 18:417-22. 2004
  3. ncbi Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study)
    Eva Gerdts
    Haukeland University Hospital, Bergen, Norway
    Am J Cardiol 89:399-402. 2002
  4. ncbi Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy)
    Eva Gerdts
    Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
    J Hypertens 20:1223-9. 2002
  5. ncbi Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study
    E Gerdts
    Institute of Medicine, University of Bergen
    Nutr Metab Cardiovasc Dis 19:306-12. 2009
  6. ncbi Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension
    P Omvik
    Institute of Internal Medicine, Department of Cardiology, Bergen, Norway
    Am Heart J 140:624-30. 2000
  7. ncbi Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus
    E Svarstad
    Renal Research Group, Institute of Medicine, University of Bergen, Norway
    Kidney Blood Press Res 24:64-70. 2001
  8. ncbi Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study)
    E Gerdts
    Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
    Am J Cardiol 87:980-3; A4. 2001
  9. ncbi Similar central hemodynamics in salt-sensitive and salt-resistant hypertensive patients
    P Omvik
    Department of Cardiology, Haukeland Hospital, Bergen, Norway
    Blood Press 8:233-41. 1999
  10. ncbi Impact of overweight and obesity on cardiac benefit of antihypertensive treatment
    E Gerdts
    Institute of Medicine, University of Bergen, N 5021, Bergen, Norway
    Nutr Metab Cardiovasc Dis 23:122-9. 2013

Collaborators

Detail Information

Publications53

  1. ncbi Correlates of left atrial size in hypertensive patients with left ventricular hypertrophy: the Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
    Eva Gerdts
    Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
    Hypertension 39:739-43. 2002
    ....
  2. ncbi Impact of age on left ventricular hypertrophy regression during antihypertensive treatment with losartan or atenolol (the LIFE study)
    E Gerdts
    Institute of Medicine, University of Bergen, Norway
    J Hum Hypertens 18:417-22. 2004
    ....
  3. ncbi Correlates of pulse pressure reduction during antihypertensive treatment (losartan or atenolol) in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study)
    Eva Gerdts
    Haukeland University Hospital, Bergen, Norway
    Am J Cardiol 89:399-402. 2002
    ....
  4. ncbi Impact of diastolic Doppler indices on exercise capacity in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy)
    Eva Gerdts
    Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
    J Hypertens 20:1223-9. 2002
    ..To assess whether Doppler evidence of impaired early diastolic relaxation during exercise is associated with lesser exercise capacity in hypertensive patients...
  5. ncbi Impact of diabetes on treatment-induced changes in left ventricular structure and function in hypertensive patients with left ventricular hypertrophy. The LIFE study
    E Gerdts
    Institute of Medicine, University of Bergen
    Nutr Metab Cardiovasc Dis 19:306-12. 2009
    ..Diabetes is associated with left ventricular hypertrophy (LVH) and impaired systolic function in hypertensive patients, but less is known about its impact on LVH regression and functional improvement during antihypertensive treatment...
  6. ncbi Long-term central hemodynamic effects at rest and during exercise of losartan in essential hypertension
    P Omvik
    Institute of Internal Medicine, Department of Cardiology, Bergen, Norway
    Am Heart J 140:624-30. 2000
    ..Losartan reduces blood pressure in patients with essential hypertension, but the long-term central hemodynamic effects at rest and during exercise are not known...
  7. ncbi Renal hemodynamic effects of captopril and doxazosin during slight physical activity in hypertensive patients with type-1 diabetes mellitus
    E Svarstad
    Renal Research Group, Institute of Medicine, University of Bergen, Norway
    Kidney Blood Press Res 24:64-70. 2001
    ....
  8. ncbi Gender differences in systolic left ventricular function in hypertensive patients with electrocardiographic left ventricular hypertrophy (the LIFE study)
    E Gerdts
    Department of Heart Disease, Haukeland University Hospital, Bergen, Norway
    Am J Cardiol 87:980-3; A4. 2001
    ..33). Thus, female gender is an independent predictor of higher systolic LV function in hypertensive patients with electrocardiographic LV hypertrophy...
  9. ncbi Similar central hemodynamics in salt-sensitive and salt-resistant hypertensive patients
    P Omvik
    Department of Cardiology, Haukeland Hospital, Bergen, Norway
    Blood Press 8:233-41. 1999
    ..It is concluded that there is no difference in central hemodynamics in salt-sensitive and salt-resistant hypertensive patients when they are on their habitual salt diet...
  10. ncbi Impact of overweight and obesity on cardiac benefit of antihypertensive treatment
    E Gerdts
    Institute of Medicine, University of Bergen, N 5021, Bergen, Norway
    Nutr Metab Cardiovasc Dis 23:122-9. 2013
    ..Less is known about the impact of BMI on improvement in left ventricular (LV) structure and function during antihypertensive treatment...
  11. ncbi Prevalence and covariates of electrocardiographic left ventricular hypertrophy in diabetic patients in Tanzania
    J J K Lutale
    Institute of Medicine and Centre for International Health, University of Bergen, Bergen, Norway
    Cardiovasc J Afr 19:8-14. 2008
    ..Therefore, the aim was to assess the prevalence of ECG-LVH in diabetic patients in Dares Salaam, Tanzania, and its relation to other cardiovascular risk factors...
  12. ncbi Factors influencing reduction in blood pressure and left ventricular mass in hypertensive type-1 diabetic patients using captopril or doxazosin for 6 months
    E Gerdts
    Department of Heart Disease, Haukeland Hospital, Bergen, Norway
    Am J Hypertens 11:1178-87. 1998
    ....
  13. ncbi Brain abscess caused by paradoxical embolization in Ebstein's anomaly
    M T Lønnebakken
    Department of Heart Disease, Haukeland University Hospital, 5021 Bergen, Norway
    Eur J Echocardiogr 9:105-6. 2008
    ..Ebstein's anomaly can remain undiagnosed until adulthood if the right ventricle, in spite of the smaller size, is haemodynamically well functioning...
  14. ncbi Change in pulse pressure/stroke index in response to sustained blood pressure reduction and its impact on left ventricular mass and geometry changes: the life study
    Vittorio Palmieri
    Division of Cardiology, Department of Medicine, Weill Medical College of Cornell University, New York, NY, USA
    Am J Hypertens 21:701-7. 2008
    ..In cross-sectional data in hypertensive subjects, brachial pulse pressure (PP)/Doppler stroke index (SVi), (PP/SVi) correlates weakly but significantly with left ventricular (LV) mass and relative wall thickness (RWT)...
  15. ncbi Association of hemoglobin delivery with left ventricular structure and function in hypertensive patients: Losartan Intervention for End Point Reduction in Hypertension Study
    Puneet Narayan
    Veterans Administration Medical Center, Washington, DC 20422, USA
    Hypertension 47:868-73. 2006
    ..Thus, in hypertensive LVH, higher oxygen delivery capacity is associated with higher LV mass and impaired early diastolic LV filling...
  16. ncbi Impact of hypertension on left ventricular hypertrophy regression and exercise capacity in patients operated for aortic valve stenosis
    Dana Cramariuc
    Institute of Medicine, University of Bergen, Bergen, Norway
    Scand Cardiovasc J 40:167-74. 2006
    ..To assess the influence of concomitant hypertension on left ventricular hypertrophy regression and exercise capacity in patients operated for aortic stenosis...
  17. ncbi Electrocardiographic strain pattern and left ventricular diastolic function in hypertensive patients with left ventricular hypertrophy: the LIFE study
    Vittorio Palmieri
    Weill Medical College of Cornell University, New York, NY 10021, USA
    J Hypertens 24:2079-84. 2006
    ....
  18. ncbi Exercise performance during losartan- or atenolol-based treatment in hypertensive patients with electrocardiographic left ventricular hypertrophy (a LIFE substudy)
    Eva Gerdts
    Institute of Medicine, University of Bergen, Bergen, Norway
    Blood Press 15:220-6. 2006
    ..The results may be explained by persistent impairment of myocardial relaxation influencing exercise capacity...
  19. ncbi Left atrial size and risk of major cardiovascular events during antihypertensive treatment: losartan intervention for endpoint reduction in hypertension trial
    Eva Gerdts
    Institute of Medicine, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    Hypertension 49:311-6. 2007
    ....
  20. ncbi Electrocardiographic characteristics and metabolic risk factors associated with inappropriately high left ventricular mass in patients with electrocardiographic left ventricular hypertrophy: the LIFE Study
    Vittorio Palmieri
    Weill Medical College of Cornell University, New York, NY 10021, USA
    J Hypertens 25:1079-85. 2007
    ....
  21. ncbi Reduced exercise capacity in genetic haemochromatosis
    Einar Skulstad Davidsen
    Department of Heart Disease, Haukeland University Hospital, University of Bergen, Norway
    Eur J Cardiovasc Prev Rehabil 14:470-5. 2007
    ..Many patients with genetic haemochromatosis complain about fatigue and reduced physical capacity. Exercise capacity, however, has not been evaluated in larger series of haemochromatosis patients treated with repeated phlebotomy...
  22. ncbi Electrocardiographic and echocardiographic detection of myocardial infarction in patients with left-ventricular hypertrophy. The LIFE Study
    Silvana Cicala
    Division of Cardiology, Weill Medical College of Cornell University, New York, NewYork 10021, USA
    Am J Hypertens 20:771-6. 2007
    ..Thus, we compared the accuracy of 2D echocardiography with Minnesota-code ECG criteria in detecting incident MI, adjudicated during serial evaluation in patients with hypertension and LVH...
  23. ncbi Gender differences in left ventricular structure and function during antihypertensive treatment: the Losartan Intervention for Endpoint Reduction in Hypertension Study
    Eva Gerdts
    Institute of Medicine, University of Bergen, Haukeland University Hospital, N 5021 Bergen, Norway
    Hypertension 51:1109-14. 2008
    ..07; P<0.01). Hypertensive women in this study retained higher left ventricular ejection fraction and stress-corrected midwall shortening in spite of less hypertrophy regression during long-term antihypertensive treatment...
  24. ncbi Left atrial systolic force in hypertensive patients with left ventricular hypertrophy: the LIFE study
    Marcello Chinali
    Weill Medical College of Cornell University, New York, NY 10021, USA
    J Hypertens 26:1472-6. 2008
    ....
  25. ncbi Effects of losartan in women with hypertension and left ventricular hypertrophy: results from the Losartan Intervention for Endpoint Reduction in Hypertension Study
    Ingrid Os
    Department of Nephrology, Ullevaal University Hospital, 0407 Oslo, Norway
    Hypertension 51:1103-8. 2008
    ....
  26. ncbi Factors influencing left ventricular structure and stress-corrected systolic function in men and women with asymptomatic aortic valve stenosis (a SEAS Substudy)
    Dana Cramariuc
    Institute of Medicine, University of Bergen, Bergen, Norway
    Am J Cardiol 101:510-5. 2008
    ..Women have higher stress-corrected indexes of systolic function independent of LV geometry or size, wall stress, older age, or more concomitant hypertension...
  27. ncbi Gender differences in regression of electrocardiographic left ventricular hypertrophy during antihypertensive therapy
    Peter M Okin
    Greenberg Division of Cardiology, Weill Cornell Medical College, New York, NY 10021, USA
    Hypertension 52:100-6. 2008
    ....
  28. ncbi Clinical impact of 'in-treatment' wall motion abnormalities in hypertensive patients with left ventricular hypertrophy: the LIFE study
    Silvana Cicala
    Division of Cardiology, Weill Cornell Medical College, New York, New York 10021, USA
    J Hypertens 26:806-12. 2008
    ..We examined whether 'in-treatment' wall motion abnormalities predicted outcome in the Losartan Intervention For Endpoint (LIFE) reduction in hypertension echocardiographic substudy...
  29. ncbi Progressive hypertrophy regression with sustained pressure reduction in hypertension: the Losartan Intervention For Endpoint Reduction study
    Richard B Devereux
    Department of Medicine, Weill Medical College of Cornell University, New York, New York 10021, USA
    J Hypertens 20:1445-50. 2002
    ..To examine the time course of left ventricular (LV) geometric response to blood pressure (BP) control during 2 years of systematic antihypertensive treatment...
  30. ncbi Impact of diabetes mellitus on regression of electrocardiographic left ventricular hypertrophy and the prediction of outcome during antihypertensive therapy: the Losartan Intervention For Endpoint (LIFE) Reduction in Hypertension Study
    Peter M Okin
    Division of Cardiology, Department of Medicine, Cornell University Medical Center, New York, NY 10021, USA
    Circulation 113:1588-96. 2006
    ....
  31. ncbi Aortic valve sclerosis and albuminuria predict cardiovascular events independently in hypertension: a losartan intervention for endpoint-reduction in hypertension (LIFE) substudy
    Michael H Olsen
    Department of Internal Medicine, Glostrup University Hospital, Glostrup, Denmark
    Am J Hypertens 18:1430-6. 2005
    ..We aimed to investigate whether they predicted cardiovascular (CV) events independently in patients with hypertension and electrocardiographic left ventricular (LV) hypertrophy...
  32. ncbi Echocardiographic wall motion abnormalities in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE Study
    Vittorio Palmieri
    Cornell Medical Center, New York, New York, USA
    Hypertension 41:75-82. 2003
    ..No significant differences were found between patients with global or segmental wall motion abnormalities...
  33. ncbi Left ventricular mass regression in the LIFE study: effect of previous antihypertensive treatment
    Gerard P Aurigemma
    Department of Medicine, Division of Cardiology, University of Massachusetts Medical School, Worcester, Massachusetts, USA
    Am J Hypertens 16:180-6. 2003
    ..Accordingly, our aim was to study the relationship between prior treatment and both baseline and 1-year echocardiographic LV mass in subjects enrolled in the Losartan Intervention For Endpoint reduction (LIFE) study...
  34. ncbi Pulse pressure/stroke index and left ventricular geometry and function: the LIFE Study
    Vittorio Palmieri
    Weill Medical College of Cornell University, New York, NY 10021, USA
    J Hypertens 21:781-7. 2003
    ..To evaluate the relationship between arterial stiffness estimated by the pulse pressure/stroke index ratio (PP/SVi) and prognostically relevant abnormalities of left ventricular geometry and function...
  35. ncbi Change in systolic left ventricular performance after 3 years of antihypertensive treatment: the Losartan Intervention for Endpoint (LIFE) Study
    Kristian Wachtell
    Copenhagen County University Hospital, Glostrup, Denmark
    Circulation 106:227-32. 2002
    ..We have shown that hypertensive patients with left ventricular (LV) hypertrophy have decreased LV midwall mechanics, but the effect of antihypertensive therapy remains unclear...
  36. ncbi Regression of hypertensive left ventricular hypertrophy by losartan compared with atenolol: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial
    Richard B Devereux
    Cornell Medical Center, 525 E 68th St, New York, NY 10021, USA
    Circulation 110:1456-62. 2004
    ..An echocardiographic substudy of the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) trial was designed to test the ability of losartan to reduce left ventricular (LV) mass more than atenolol...
  37. ncbi Change in diastolic left ventricular filling after one year of antihypertensive treatment: The Losartan Intervention For Endpoint Reduction in Hypertension (LIFE) Study
    Kristian Wachtell
    Copenhagen County University Hospital, Glostrup, Denmark
    Circulation 105:1071-6. 2002
    ..It is well established that hypertensive patients with left ventricular (LV) hypertrophy have impaired diastolic filling. However, the impact of antihypertensive treatment and LV mass reduction on LV diastolic filling remains unclear...
  38. ncbi Change of left ventricular geometric pattern after 1 year of antihypertensive treatment: the Losartan Intervention For Endpoint reduction in hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Copenhagen County University Hospital, Glostrup, Denmark
    Am Heart J 144:1057-64. 2002
    ..Patients with hypertension have different types of left ventricular (LV) geometry, but the impact of blood pressure (BP) reduction on LV geometry change during antihypertensive treatment remains unclear...
  39. ncbi Essential hypertension in women
    Ingrid Os
    Department of Pharmacotherapeutics, University of Oslo, Oslo, Norway
    Blood Press 13:272-8. 2004
  40. ncbi Relation of left ventricular geometry and function to aortic root dilatation in patients with systemic hypertension and left ventricular hypertrophy (the LIFE study)
    Jonathan N Bella
    Cornell Medical Center, New York, New York, USA
    Am J Cardiol 89:337-41. 2002
  41. ncbi Prognostic significance of left ventricular mass change during treatment of hypertension
    Richard B Devereux
    Department of Medicine, New York Presbyterian Hospital, Cornell Medical Center, New York, NY 10021, USA
    JAMA 292:2350-6. 2004
    ..Increased baseline left ventricular (LV) mass predicts cardiovascular (CV) complications of hypertension, but the relation between lower LV mass and outcome during treatment for hypertension is uncertain...
  42. ncbi Aortic valve sclerosis relates to cardiovascular events in patients with hypertension (a LIFE substudy)
    Michael H Olsen
    Department of Clinical Physiology and Nuclear Medicine, Glostrup University Hospital, DK 2600 Glostrup, Denmark
    Am J Cardiol 95:132-6. 2005
    ..AV sclerosis was associated with several CV risk factors and predicted CV events independently of prevalent CV disease and traditional CV risk factors, including LV mass and ejection fraction...
  43. ncbi Left ventricular structure and function in sedentary and physically active subjects with left ventricular hypertrophy (the LIFE Study)
    Kurt Boman
    Department of Medicine, Skellefteå County Hospital and Umeå University, 93186 Skellefteå, Sweden
    Am J Cardiol 95:280-3. 2005
    ..Patients with left ventricular hypertrophy had higher heart rates, left ventricular mass, and left atrial size independent of gender, blood pressure, or body mass index than physically active patients...
  44. ncbi Cardiovascular morbidity and mortality in hypertensive patients with a history of atrial fibrillation: The Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    J Am Coll Cardiol 45:705-11. 2005
    ..We assessed the impact of antihypertensive treatment in hypertensive patients with electrocardiographic (ECG) left ventricular (LV) hypertrophy and a history of atrial fibrillation (AF)...
  45. ncbi Angiotensin II receptor blockade reduces new-onset atrial fibrillation and subsequent stroke compared to atenolol: the Losartan Intervention For End Point Reduction in Hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Glostrup University Hospital, Glostrup, Denmark
    J Am Coll Cardiol 45:712-9. 2005
    ..This study was designed to evaluate whether different antihypertensive treatment regimens with similar blood pressure reduction have different effects on new-onset atrial fibrillation (AF)...
  46. ncbi Urine albumin/creatinine ratio and echocardiographic left ventricular structure and function in hypertensive patients with electrocardiographic left ventricular hypertrophy: the LIFE study. Losartan Intervention for Endpoint Reduction
    Kristian Wachtell
    Laboratory of Cardiology, Department of Medicine, Copenhagen County University Hospital, Glostrup, Denmark
    Am Heart J 143:319-26. 2002
    ..However, the relationship between these markers of cardiovascular damage has not been evaluated in a large hypertensive population...
  47. ncbi Intensive lipid lowering with simvastatin and ezetimibe in aortic stenosis
    Anne B Rossebø
    Division of Cardiology, Aker University Hospital, Trondheimsveien 235, N 0514 Oslo, Norway
    N Engl J Med 359:1343-56. 2008
    ..Hyperlipidemia has been suggested as a risk factor for stenosis of the aortic valve, but lipid-lowering studies have had conflicting results...
  48. ncbi [Hypertension and heart disease]
    Eva Gerdts
    Institutt for indremedisin, Universitetet i Bergen, 5020 Bergen
    Tidsskr Nor Laegeforen 124:802-5. 2004
    ..Heart failure symptoms may be subtle in hypertension, like tiredness or reduced physical capacity. Echocardiography can reveal subclinical heart disease as well as serve as a guide to correct diagnosis and treatment...
  49. ncbi Blood pressure measurements by the Keito machine. Evaluation versus office blood pressure by physicians
    Eva M Staal
    Department of Heart Disease; Institute of Medicine, Haukeland University Hospital, Bergen, Norway
    Blood Press Monit 9:167-72. 2004
    ..However, the difference can be much larger in individual patients. Therefore, the Keito machine cannot be recommended for medical screening of HT or as a replacement for follow-up by physicians...
  50. ncbi Relation of impaired left ventricular filling to systolic midwall mechanics in hypertensive patients with normal left ventricular systolic chamber function: the Losartan Intervention for Endpoint Reduction in Hypertension (LIFE) study
    Kristian Wachtell
    Department of Medicine, Copenhagen County University Hospital, Glostrup, Denmark
    Am Heart J 148:538-44. 2004
    ..LV systolic midwall shortening (MWS) may be impaired in hypertensive patients with normal LV ejection fraction. However, it is unclear whether impaired LV filling is related to depressed systolic midwall mechanics...
  51. ncbi Effect of losartan versus atenolol on aortic valve sclerosis (a LIFE substudy)
    Michael H Olsen
    Glostrup University Hospital, Glostrup, Denmark
    Am J Cardiol 94:1076-80. 2004
    ....
  52. ncbi Design and baseline characteristics of the simvastatin and ezetimibe in aortic stenosis (SEAS) study
    Anne B Rossebø
    Division of Cardiology, Aker University Hospital, Oslo, Norway
    Am J Cardiol 99:970-3. 2007
    ..4+/-0.7 mmol/L (126 mg/dl). The SEAS Study is the largest randomized trial to date in patients with AS and will allow determination of the prognostic value of aggressive lipid lowering in such patients...
  53. ncbi Left atrial volume in patients with asymptomatic aortic valve stenosis (the Simvastatin and Ezetimibe in Aortic Stenosis study)
    Morten Dalsgaard
    Department of Cardiology, Copenhagen University Hospital Rigshospitalet, Copenhagen, Denmark
    Am J Cardiol 101:1030-4. 2008
    ..Furthermore, LA volume is related to AVA even when adjusting for other known risk factors for increased LA volume including of measurements of diastolic function...